All news

Spineway, specialist in designing innovative surgical implants and instruments for treating severe disorders of the spinal column, expects the gradual return of spinal surgeries worldwide. In order to meet the needs of this recovery, the company has welcomed some of its employees back on the premises after implementing the new health and safety rules required following the lifting of the COVID-19 stay-at-home order to lessen the risk of the virus spreading to employees. For now, employees whose jobs are conducive to working remotely remain at home. This will change as needs evolve due to the return to activity and the health authorities’ recommendations.

Spineway, specialized in innovative implants for the treatment of disorders of the spinal column (spine), showed a sharp increase in sales for the month of December 2020 (+30% compared with December 2019), allowing it to post revenue of €1 068K for the fourth quarter, up 21% compared with the third quarter of 2020. This positive dynamism brough the Group’s annual revenue to €3 380K and decreased the gap with 2019 (-33%) for a year that was deeply affected by the COVID crisis.

Spineway, specialized in the treatment of severe disorders of the spine, announces the launch of a new concept: MISTI (acronym for Minimally Invasive Spine Total Instrumentation).

Spineway, specialist in designing innovative surgical implants and instruments for treating severe disorders of the spinal column, announces the signature of an exclusive agreement for the distribution of its products in Japan with MURANAKA Medical Instruments.

SPINEWAY (ISIN : FR0011398874 – ALSPW), specialized in the treatment of severe disorders of the spine, announced today its 2021 financial calendar.

Spineway, specialized in the treatment of severe disorders of the spine, announces the publication of a scientific article in the renowned scientific journal Spine Deformity1 highlighting the benefits of the Mont-Blanc 3D+ technology for the treatment of adolescent idiopathic scoliosis.

Spineway’s Board of Directors, at a meeting held on 15 April 2020 chaired by Stéphane Le Roux, closed the 2019 annual accounts. The Group’s Statutory Auditors have audited these accounts and their reports are being prepared.

In keeping with its development strategy, Spineway wishes to be in a position to take advantage of any and all external-growth opportunities that could create value and new synergies. To this end, Spineway decided to launch a new subscription phase for Convertible Bonds with warrants.

The first half of this year was understandably affected by the health crisis caused by the worldwide Coronavirus pandemic, which led to the cancellation of all non-essential surgeries. During this unprecedented period, the Spineway group was fully committed to providing the best possible services to its direct clients in France and its international distribution partners. These efforts allowed the Group to keep its revenue for the second quarter at close to 30% of that of the previous year despite a very complicated international situation, resulting in half-year revenue of €1 432K as at 30 June 2020 (-45% compared with HY1 2019)